Crizotinib in treatment of lung cancer
Lung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Muller Journal of Medical Sciences and Research |
| Subjects: | |
| Online Access: | http://www.mjmsr.net/article.asp?issn=0975-9727;year=2017;volume=8;issue=2;spage=65;epage=67;aulast=Singh |